70,566 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Public Sector Pension Investment Board

Public Sector Pension Investment Board purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 70,566 shares of the company’s stock, valued at approximately $11,079,000. Public Sector Pension Investment Board owned approximately 0.21% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in TransMedics Group during the 2nd quarter worth approximately $47,000. USA Financial Formulas acquired a new position in shares of TransMedics Group in the 3rd quarter valued at approximately $55,000. J.Safra Asset Management Corp raised its position in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares in the last quarter. Signaturefd LLC raised its position in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This represents a 12.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,958 shares of company stock valued at $3,470,328. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Trading Up 8.1 %

Shares of NASDAQ TMDX opened at $87.11 on Friday. TransMedics Group, Inc. has a 12 month low of $67.77 and a 12 month high of $177.37. The company has a market cap of $2.92 billion, a price-to-earnings ratio of 92.67 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The business has a fifty day simple moving average of $113.26 and a 200-day simple moving average of $136.45.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.12) earnings per share. Sell-side analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TMDX shares. TD Cowen cut their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Stephens upped their target price on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler cut their target price on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Needham & Company LLC reiterated a “hold” rating and issued a $109.00 price target on shares of TransMedics Group in a report on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.